Creative Planning grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 96,307 shares of the medical research company’s stock after purchasing an additional 8,391 shares during the quarter. Creative Planning’s holdings in Amgen were worth $16,748,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after acquiring an additional 3,601,087 shares during the period. FMR LLC raised its holdings in Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after acquiring an additional 2,587,041 shares during the period. Renaissance Technologies LLC raised its holdings in Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after acquiring an additional 986,700 shares during the period. BlackRock Inc. raised its holdings in Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after acquiring an additional 909,689 shares during the period. Finally, Nordea Investment Management AB raised its holdings in Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after acquiring an additional 806,119 shares during the period. Institutional investors and hedge funds own 78.03% of the company’s stock.
Several research analysts recently commented on AMGN shares. BMO Capital Markets reiterated a “market perform” rating and issued a $198.00 target price on shares of Amgen in a report on Thursday, October 26th. BidaskClub upgraded shares of Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday, December 2nd. Goldman Sachs Group downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Amgen currently has a consensus rating of “Hold” and a consensus price target of $191.84.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $182.43 on Thursday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 12-month low of $152.16 and a 12-month high of $201.23. The firm has a market cap of $131,848.47, a PE ratio of 70.98, a PEG ratio of 2.18 and a beta of 1.42.
Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same quarter last year, the firm posted $2.89 earnings per share. Amgen’s revenue was down 2.7% on a year-over-year basis. analysts anticipate that Amgen, Inc. will post 13.21 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is a positive change from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s payout ratio is 205.45%.
Amgen announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.